Presentation Theater: Advanced Formulation of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer, mCRPC

Description

Yonsa, a novel, fine-particle formulation of abiraterone acetate, provides an oral treatment option, in combination with methylprednisolone, for patients with metastatic CRPC. In clinical trials, 500-mg dosing of the fine-particle abiraterone acetate formulation in combination with 4-mg of methylprednisolone demonstrated therapeutic equivalence to 1000-mg dosing of the original formulation, with similar reductions in PSA.

David Berz, MD, PhD, MPH

Presented by Sun Pharmaceutical Industries.

 

 
 
 
Interest: Presentation Theater
Session Time Slot(s): 
Date: 
Tuesday, October 29
Time: 
6:00 PM - 7:30 PM
Room: 
Hilton Anatole Dallas - Cortez A